This could be a game-changer when it comes to biologics.
As explained on Biopharma Reporter, the polymer pill has a pH-sensitive outer layer.
"When ingested, the outer layer dissolves in the intestine, exposing a tiny valve that releases citric acid and sodium bicarbonate," according to the article. "These chemicals react, creating energy which inflates a balloon-like structure surrounded by tiny sugar needles preloaded with the drug that lodges itself into the intestinal wall, delivering the API painlessly."
According to a press release, after successful completion of the feasibility studies, which will be conducted by Rani Therapeutics over the next 18-24 months, Novartis will have the right to enter into a more extensive collaboration with Rani and/or license Rani's technology for specific fields of use.
" We understand the magnitude of the problem we are pursuing, and we are confident that our approach has the potential to radically change the way biologics are administered to patients," said Mir Imran, Chairman and CEO, of Rani Therapeutics.